Efficacy and Safety of AGN-199201 in Patients With Persistent Erythema Associated With Rosacea

Study Identifier
199201-004
CT.gov Identifier
NCT02131636
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Study Details

Medical Condition
  • Dermatology - Other
    • Study Drug
  • AGN-199201
  • Vehicle to AGN-199201
    • Phase
    Phase 3
    Sex
    Female & Male
    Age
    18+ years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    -Moderate to severe persistent facial erythema associated with rosacea.
    Exclusion Criteria:
    * Greater than 3 inflammatory lesions on the face * Current treatment with monoamine oxidase (MAO) inhibitors * Raynaud's syndrome, narrow angle glaucoma, orthostatic hypotension, scleroderma or Sjogren's syndrome.

    Protocol Summary

    This study will evaluate the safety and efficacy of AGN-199201 once daily compared to vehicle for the treatment of persistent moderate to severe facial erythema associated with rosacea.

    Study Locations

    Location
    Status
    Location
    Lynchburg, Virginia, United States
    Status
    Not applicable